Relations of Change in Plasma Levels of LDL‐C, Non‐HDL‐C and apoB With Risk Reduction From Statin Therapy: A Meta‐Analysis of Randomized Trials

  • Thanassoulis, George
  • Williams, Ken
  • Ye, Keying
  • Brook, Robert
  • Couture, Patrick
  • Lawler, Patrick R.
  • de Graaf, Jacqueline
  • Furberg, Curt D.
  • Sniderman, Allan
Publication date
December 2014
Publisher
Ovid Technologies (Wolters Kluwer Health)
ISSN
2047-9980
Journal
Journal of the American Heart Association
Citation count (estimate)
49

Abstract

Background: Identifying the best markers to judge the adequacy of lipid‐lowering treatment is increasingly important for coronary heart disease (CHD) prevention given that several novel, potent lipid‐lowering therapies are in development. Reductions in LDL‐C, non‐HDL‐C, or apoB can all be used but which most closely relates to benefit, as defined by the reduction in events on statin treatment, is not established. Methods and Results: We performed a random‐effects frequentist and Bayesian meta‐analysis of 7 placebo‐controlled statin trials in which LDL‐C, non‐HDL‐C, and apoB values were available at baseline and at 1‐year follow‐up. Summary level data for change in LDL‐C, non‐HDL‐C, and apoB were related to the relative risk reduction from s...

Extracted data

We use cookies to provide a better user experience.